Lynparza(olaparib)
Lynparza (olaparib) is a small molecule pharmaceutical. Olaparib was first approved as Lynparza on 2014-12-16. It is used to treat ovarian neoplasms in the USA. It has been approved in Europe to treat ovarian neoplasms. The pharmaceutical is active against poly [ADP-ribose] polymerase 1 and poly [ADP-ribose] polymerase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Lynparza (discontinued: Lynparza)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Olaparib
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LYNPARZA | AstraZeneca | N-208558 RX | 2017-08-17 | 2 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lynparza | New Drug Application | 2023-11-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| ovarian neoplasms | EFO_0003893 | D010051 | C56 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
OLAPARIB, LYNPARZA, ASTRAZENECA | |||
| 2027-05-08 | ODE-306 | ||
| 2026-12-27 | ODE-283 | ||
| 2025-12-19 | ODE-226 | ||
| 2025-03-11 | I-885 | ||
| 2024-08-17 | ODE-180, ODE-181 | ||
| 2023-05-19 | I-832 | ||
| 2023-05-08 | I-831 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Olaparib, Lynparza, Astrazeneca | |||
| 8859562 | 2031-08-04 | U-1634, U-2101, U-2103, U-2480, U-2482, U-2483, U-2716, U-2819, U-2820, U-2821, U-2822, U-2823, U-2824, U-2832, U-2833, U-3333, U-3631 | |
| 8475842 | 2029-12-31 | DP | |
| 11633396 | 2029-10-07 | DP | |
| 8247416 | 2028-09-24 | DP | |
| 8071579 | 2027-08-12 | U-2101, U-2103, U-2480, U-2482, U-2483, U-2716, U-2819, U-2820, U-2821, U-2822, U-2823, U-2824, U-2832, U-2833, U-3333, U-3631 | |
| 8143241 | 2027-08-12 | U-1634, U-2101, U-2103, U-2480, U-2482, U-2483, U-2716, U-2819, U-2820, U-2821, U-2822, U-2823, U-2824, U-2832, U-2833, U-3333, U-3631 | |
| 7449464 | 2024-10-11 | DS, DP | |
| 7981889 | 2024-10-11 | DS, DP | |
| 8912187 | 2024-03-12 | U-1634, U-2101, U-2480, U-2482, U-2483, U-2819, U-2820, U-2821, U-2822, U-2823, U-2824, U-3333 | |
| 9169235 | 2024-03-12 | U-2832, U-2833, U-3631 | |
| 9566276 | 2024-03-12 | U-2716 | |
HCPCS
No data
Clinical
Clinical Trials
456 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 30 | 58 | 19 | 3 | 21 | 119 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 39 | 54 | 10 | 2 | 6 | 98 |
| Neoplasms | D009369 | — | C80 | 49 | 36 | — | 1 | 5 | 83 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 15 | 40 | 15 | 3 | 16 | 83 |
| Carcinoma | D002277 | — | C80.0 | 20 | 36 | 2 | 1 | 1 | 54 |
| Prostatic neoplasms | D011471 | — | C61 | 17 | 32 | 5 | 1 | 5 | 53 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 9 | 18 | 4 | 1 | 2 | 27 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 6 | 11 | 4 | 1 | 1 | 20 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | 4 | — | 1 | — | 6 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | — | — | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 13 | 26 | 4 | — | 1 | 39 |
| Adenocarcinoma | D000230 | — | — | 9 | 25 | 4 | — | — | 33 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 11 | 17 | 1 | — | 2 | 28 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 12 | 17 | 3 | — | — | 26 |
| Fallopian tube neoplasms | D005185 | — | — | 9 | 15 | 3 | — | 1 | 24 |
| Small cell lung carcinoma | D055752 | — | — | 8 | 16 | 1 | — | — | 20 |
| Hereditary breast and ovarian cancer syndrome | D061325 | — | — | 8 | 10 | 2 | — | 1 | 18 |
| Non-small-cell lung carcinoma | D002289 | — | — | 6 | 10 | 3 | — | — | 17 |
| Serous cystadenocarcinoma | D018284 | — | — | 8 | 10 | 2 | — | — | 17 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 9 | 3 | 1 | — | — | 12 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | — | — | 14 | 23 | — | — | 1 | 35 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 6 | 5 | — | — | — | 9 |
| Lymphoma | D008223 | — | C85.9 | 4 | 3 | — | — | — | 7 |
| Glioma | D005910 | EFO_0000520 | — | 1 | 7 | — | — | — | 7 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | 4 | — | — | — | 6 |
| Glioblastoma | D005909 | EFO_0000515 | — | 3 | 3 | — | — | — | 6 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 6 | — | — | — | 6 |
| Melanoma | D008545 | — | — | 2 | 3 | — | — | — | 5 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 4 | — | — | — | 5 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 3 | 3 | — | — | — | 5 |
Show 83 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hodgkin disease | D006689 | — | C81 | 2 | — | — | — | — | 2 |
| Head and neck neoplasms | D006258 | — | — | 2 | — | — | — | — | 2 |
| Squamous cell neoplasms | D018307 | — | — | 2 | — | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | 1 | — | — | — | — | 1 |
Show 19 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancytopenia | D010198 | HP_0001876 | D61.81 | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Olaparib |
| INN | olaparib |
| Description | Olaparib is a member of the class of N-acylpiperazines obtained by formal condensation of the carboxy group of 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoic acid with the free amino group of N-(cyclpropylcarbonyl)piperazine; used to treat advanced ovarian cancer. It has a role as an antineoplastic agent, an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor and an apoptosis inducer. It is a N-acylpiperazine, a member of cyclopropanes, a member of monofluorobenzenes and a member of phthalazines. |
| Classification | Small molecule |
| Drug class | poly-ADP-ribose polymerase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 763113-22-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL521686 |
| ChEBI ID | 83766 |
| PubChem CID | 23725625 |
| DrugBank | DB09074 |
| UNII ID | WOH1JD9AR8 (ChemIDplus, GSRS) |
Target
Agency Approved
PARP2
PARP2
Organism
Homo sapiens
Gene name
PARP2
Gene synonyms
ADPRT2, ADPRTL2
NCBI Gene ID
Protein name
poly [ADP-ribose] polymerase 2
Protein synonyms
ADP-ribosyltransferase (NAD+; poly(ADP-ribose) polymerase)-like 2, ADP-ribosyltransferase diphtheria toxin-like 2, ADPRT-2, ARTD2, DNA ADP-ribosyltransferase PARP2, hPARP-2, NAD(+) ADP-ribosyltransferase 2, pADPRT-2, poly (ADP-ribose) polymerase family, member 2, poly (ADP-ribosyl) transferase-like 2, Poly[ADP-ribose] synthase 2, poly[ADP-ribose] synthetase 2, Protein poly-ADP-ribosyltransferase PARP2
Uniprot ID
Mouse ortholog
Parp2 (11546)
poly [ADP-ribose] polymerase 2 (Q99N29)
Alternate
TNKS
TNKS
Organism
Homo sapiens
Gene name
TNKS
Gene synonyms
PARP5A, PARPL, TIN1, TINF1, TNKS1
NCBI Gene ID
Protein name
poly [ADP-ribose] polymerase tankyrase-1
Protein synonyms
ADP-ribosyltransferase diphtheria toxin-like 5, ARTD5, Poly [ADP-ribose] polymerase 5A, Protein poly-ADP-ribosyltransferase tankyrase-1, TANK1, Tankyrase I, tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase, Tankyrase-1, TNKS-1, TRF1-interacting ankyrin-related ADP-ribose polymerase, TRF1-interacting ankyrin-related ADP-ribose polymerase 1
Uniprot ID
Mouse ortholog
Tnks (21951)
poly [ADP-ribose] polymerase tankyrase-1 (Q8BX62)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Lynparza – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Lynparza – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 19,591 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,793 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use